| Literature DB >> 30060703 |
Peter C Rockers1, Michael R Reich2, Hannah Kettler3, Veronika J Wirtz1.
Abstract
The pharmaceutical industry has confirmed its commitment to partnering with other actors to achieve the Sustainable Development Goals. There is a unique opportunity for the industry, academia, and other global health stakeholders to come together and strengthen institutions for measuring industry-led access-to-medicines (IL-AtM) programs. We propose five critical elements of the institutional context for measurement of IL-AtM programs that should be strengthened: (1) standards for measurement; (2) platforms for learning; (3) systems for transparency; (4) mechanisms for accountability; and (5) investments for sustainability. Evidence about what works would help direct future investments toward more effective programs, to the benefit of industry and society.Keywords: accountability; evaluation; industry; medicines
Mesh:
Year: 2018 PMID: 30060703 DOI: 10.1080/23288604.2018.1483710
Source DB: PubMed Journal: Health Syst Reform ISSN: 2328-8620